BioSpace News Archive

Synbal, Inc., a biotechnology company developing non-viral, cell-based gene therapy candidates for rare diseases, cancer, autoimmune and degenerative diseases, has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute.

Call9, a telehealth pioneer for the nursing home industry, responded today to new data released by the Centers for Medicare & Medicaid Services (CMS) that provides facility-specific performance information for the fiscal year 2019 Skilled Nursing Facility Value-Based Purchasing Program.

National HME, Inc., announced that it has expanded its existing relationship with New Mountain Finance Corporation (“NMFC”), an affiliate of New Mountain Capital, LLC.

FestWorld Magazine, will launch on March 9, 2019. www.festworldmag.com

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA)

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (Nasdaq: TRPX), announced on November 27, 2018 that the Company has entered into a securities purchase agreement with YA II PN Ltd., a fund managed by Yorkville Advisors Global, for the sale in a private placement of up to $2.5 million in principal amount of unsecured convertible debentures (the “Debentures”).

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host an analyst and investor day on Tuesday, December 11, 2018 from 8:30 a.m. ET to 11:00 a.m. ET in New York City.

Navidea Biopharmaceuticals, Inc. today announced the appointment of Michael Rosol, PhD as Chief Medical Officer of Navidea, effective December 17, 2018.

The Board of Directors of Invacare Corporation announced that it declared a cash dividend of $.0125 per share on its common shares payable January 17, 2019 to shareholders of record on January 4, 2019.